Monte Net Income From Continuing Ops from 2010 to 2026
| GLUE Stock | USD 21.36 0.23 1.09% |
Net Loss | First Reported 2020-03-31 | Previous Quarter -12.3 M | Current Value -27.1 M | Quarterly Volatility 18.6 M |
Check Monte Rosa financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Monte Rosa's main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Depreciation And Amortization of 9.8 M or Interest Expense of 4.5 M, as well as many indicators such as Price To Sales Ratio of 5.42, Dividend Yield of 0.0 or PTB Ratio of 2.17. Monte financial statements analysis is a perfect complement when working with Monte Rosa Valuation or Volatility modules.
Monte | Net Income From Continuing Ops | Build AI portfolio with Monte Stock |
Analyzing Monte Rosa's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Monte Rosa's current valuation and future prospects.
Latest Monte Rosa's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Monte Rosa Therapeutics over the last few years. It is Monte Rosa's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Monte Rosa's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Monte Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (37,379,500) | |
| Coefficient Of Variation | (110.55) | |
| Mean Deviation | 35,046,529 | |
| Median | (7,740,000) | |
| Standard Deviation | 41,321,657 | |
| Sample Variance | 1707.5T | |
| Range | 125.1M | |
| R-Value | (0.77) | |
| Mean Square Error | 746.3T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (6,286,686) | |
| Total Sum of Squares | 27319.7T |
Monte Net Income From Continuing Ops History
About Monte Rosa Financial Statements
Monte Rosa stakeholders use historical fundamental indicators, such as Monte Rosa's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Monte Rosa investors may analyze each financial statement separately, they are all interrelated. For example, changes in Monte Rosa's assets and liabilities are reflected in the revenues and expenses on Monte Rosa's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Monte Rosa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -65.4 M | -68.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:Check out the analysis of Monte Rosa Correlation against competitors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.